Did PIONEER-1 have a formal extension study?

No. PIONEER-1 ended at 26 weeks with a 5-week post-treatment follow-up (to week 31). There was no protocol-defined extension. Long-term durability data come from other PIONEER trials (PIONEER-2, -4, -7, -8) that ran for 52 weeks and from post-approval real-world analyses.

How much does A1C rebound after stopping oral semaglutide?

The 5-week washout period in PIONEER-1 showed partial regression of A1C improvement. While exact post-washout values vary by patient, the pattern is consistent with other GLP-1 receptor agonists: glycemic control deteriorates within weeks of discontinuation, typically returning toward baseline over 2 to 3 months.

Is the 1.5% A1C reduction sustained at one year?

Not exactly 1.5%, but close. In 52-week PIONEER trials using the 14 mg dose, A1C reductions of 1.2 to 1.3% were maintained. The slight attenuation from peak reflects normal pharmacologic kinetics and regression-to-mean, not treatment failure.

Were there any new safety signals in longer PIONEER trials?

No unexpected safety signals emerged in the 52-week PIONEER trials. GI side effects (nausea, diarrhea) remained the most common adverse events but decreased in frequency after the first 8 to 12 weeks. Pancreatitis and retinopathy events were rare.

How does real-world A1C reduction compare to PIONEER-1 results?

Real-world data typically show A1C reductions of 1.0 to 1.2% at 6 months, modestly lower than PIONEER-1's 1.5%. The difference reflects variable adherence to the strict dosing requirements and less rigorous patient selection compared to a clinical trial setting.

Does oral semaglutide reduce cardiovascular risk?

The PIONEER program was not powered to assess cardiovascular outcomes. The dedicated SOUL cardiovascular outcomes trial for oral semaglutide, which reported results in 2024, demonstrated a significant reduction in major adverse cardiovascular events.

What is the difference between treatment-policy and trial-product estimands in PIONEER-1?

The treatment-policy estimand includes all randomized patients regardless of whether they discontinued treatment or started rescue medication. The trial-product estimand censors data after these events. For assessing drug efficacy in patients who tolerate and continue therapy, the trial-product estimand is more informative, and it showed slightly larger A1C reductions.

Why is oral semaglutide less effective in practice than in PIONEER-1?

The dosing protocol is demanding: patients must take the tablet on an empty stomach with no more than 120 mL of plain water, then wait at least 30 minutes before eating, drinking, or taking other medications. In clinical trials, adherence to this protocol was closely monitored. In practice, inconsistent adherence reduces drug absorption and blunts the glycemic effect.

Has oral semaglutide been compared head-to-head with injectable semaglutide?

Not in a Western population at standard doses. PIONEER-9 and PIONEER-10 compared the two formulations in Japanese patients using Japan-specific dosing. A direct comparison of oral 14 mg daily versus injectable 1 mg weekly in a global population has not been published.

Should patients with diabetic retinopathy avoid oral semaglutide?

Oral semaglutide has not shown a clear retinopathy signal in the PIONEER program. The ADA recommends retinal screening before starting any GLP-1 receptor agonist in patients with pre-existing retinopathy, particularly when rapid A1C improvement is anticipated, as fast glucose lowering may transiently worsen retinopathy regardless of the drug used.

PIONEER-1 Extension Data and What Happened After the Trial Ended

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for PIONEER-1 Extension Data and What Happened After the Trial Ended Image: HealthRX.com clinical image

At a glance

Trial: PIONEER-1 (NCT02906930)
N: 703 adults with type 2 diabetes on diet and exercise alone
Intervention: Oral semaglutide 3 mg, 7 mg, or 14 mg once daily
Comparator: Placebo
Duration: 26 weeks (primary), with an in-trial observation period extending to week 31
Primary endpoint: Change in A1C from baseline (treatment-policy estimand)
Key result: A1C reduction of 1.5% (14 mg) vs. 0.02% (placebo), p < 0.001
Primary source: Aroda VR et al., Diabetes Care 2019

Why the 26-Week Window Leaves Questions Unanswered

PIONEER-1 was a dose-finding, placebo-controlled registration trial. Its 26-week primary endpoint was chosen to satisfy regulatory requirements for glycemic efficacy, not to characterize long-term durability. Two features of the trial design are important when thinking about what comes next.

First, the trial enrolled drug-naive patients managed with diet and exercise alone. That population tends to have relatively preserved beta-cell function, which means early A1C drops can be dramatic but may not predict what happens in patients on background metformin or insulin. Second, the protocol included a 5-week follow-up observation after the treatment period ended (weeks 26 through 31). During those five weeks, patients who had been on semaglutide were off drug. The published data from that washout window show partial regression of glycemic improvement, confirming that oral semaglutide's effect is treatment-dependent, not disease-modifying.

That washout observation is clinically meaningful. It tells prescribers that stopping oral semaglutide will lead to A1C drift, a pattern consistent with injectable semaglutide and other GLP-1 receptor agonists.

What Other PIONEER Trials Tell Us About Durability

PIONEER-1 itself had no formal extension study. The durability question is instead addressed by the longer trials in the same program.

PIONEER-2 (semaglutide 14 mg vs. empagliflozin 25 mg) ran for 52 weeks. At week 52, oral semaglutide maintained a 1.3% A1C reduction from baseline, compared with 0.9% for empagliflozin. The difference between week-26 and week-52 results (roughly 0.2 percentage points of attenuation) is small enough that most endocrinologists consider the effect durable on continued therapy.

PIONEER-7 used a flexible dosing design over 52 weeks, and PIONEER-8 tested oral semaglutide as add-on to insulin over 52 weeks. Both showed sustained A1C reductions through one year, with no unexpected late safety signals.

Durability Assessment Framework: PIONEER-1 in Context

The table below synthesizes glycemic outcomes across PIONEER trials to estimate durability of the 14 mg dose. This cross-trial comparison was not published in any single paper; HealthRX.com assembled it from individual trial publications to help clinicians assess the trajectory of oral semaglutide's A1C effect over time.

| Trial | Duration | Baseline A1C | A1C Change (14 mg or equivalent) | Population | |---|---|---|---|---| | PIONEER-1 | 26 wk | 8.0% | -1.5% | Drug-naive | | PIONEER-2 | 52 wk | 8.1% | -1.3% | On metformin | | PIONEER-4 | 52 wk | 8.0% | -1.3% | On metformin ± SGLT2i | | PIONEER-7 | 52 wk | 8.3% | -1.3% (flex dose) | On 1-2 OADs | | PIONEER-8 | 52 wk | 8.2% | -1.3% | On insulin ± metformin |

The pattern across trials is consistent: the steep initial A1C decline seen at 26 weeks (~1.5%) settles to approximately 1.2 to 1.3% at 52 weeks. This is not failure. It reflects the normal glycemic trajectory in which the maximal pharmacologic effect plateaus and minor regression-to-mean occurs. Comparable attenuation is seen with injectable semaglutide and dulaglutide at similar time horizons.

The Regression-to-Mean Problem

Some of the apparent attenuation between 26 and 52 weeks is statistical, not biological. PIONEER-1 enrolled patients at a mean baseline A1C of 8.0%. Patients with higher baseline values tend to show larger initial drops, partly because measurement variability inflates extreme readings. When those extreme values regress toward the population mean on repeat testing, it can look like the drug is losing effect.

The PIONEER-1 publication reported results using two estimands: a "treatment-policy" estimand (which includes patients who discontinued or added rescue medication) and a "trial-product" estimand (which censors data after discontinuation). The trial-product estimand showed slightly larger A1C reductions at 14 mg (-1.5% vs. -1.4% for treatment-policy), confirming that discontinuation and rescue therapy partially diluted the treatment-policy result.

For clinicians interpreting durability, the trial-product estimand is the more useful lens. It answers: "What happens to patients who stay on drug?" The answer, across the PIONEER program, is that A1C reductions remain clinically significant through at least 52 weeks.

Safety Signals That Emerged Over Time

PIONEER-1's 26-week safety profile was dominated by GI events (nausea in 16% of the 14 mg group, diarrhea in 5%). The question is whether new signals appeared with longer exposure.

GI Tolerability

Across the 52-week PIONEER trials, nausea was most common during the first 8 to 12 weeks and decreased thereafter. This is consistent with the dose-escalation schedule built into oral semaglutide prescribing (4 weeks at 3 mg, 4 weeks at 7 mg, then 14 mg). Late-onset GI events were uncommon.

Pancreatitis and Pancreatic Safety

Acute pancreatitis has been a regulatory concern for GLP-1 receptor agonists since the exenatide era. Across the entire PIONEER program (N > 9,000), events were rare and not statistically different from comparators. The FDA label for Rybelsus includes pancreatitis in the warnings section based on class-level concern rather than a specific PIONEER signal.

Diabetic Retinopathy

The SUSTAIN-6 trial of injectable semaglutide raised a retinopathy signal (HR 1.76). In the PIONEER program, diabetic retinopathy events were numerically rare, and PIONEER-1's drug-naive population had low baseline retinopathy prevalence. No clear oral-semaglutide-specific retinopathy signal has emerged, but the ADA Standards of Care recommend retinal screening before starting any GLP-1 RA in patients with existing retinopathy, especially if rapid A1C improvement is expected.

Body Weight

PIONEER-1 showed dose-dependent weight loss: -2.3 kg at 7 mg and -3.7 kg at 14 mg vs. -1.4 kg for placebo at 26 weeks. In the 52-week PIONEER trials, weight loss was maintained or modestly increased, consistent with the trajectory seen in injectable semaglutide cardiovascular outcomes trials.

Post-Approval Real-World Evidence

Since Rybelsus received FDA approval in September 2019, several real-world database analyses have examined outcomes beyond clinical trial settings.

A 2022 retrospective cohort study using US claims data found that patients prescribed oral semaglutide had A1C reductions of approximately 1.0 to 1.2% at 6 months in clinical practice, slightly lower than the 1.5% seen in PIONEER-1. This gap is expected. Trial populations are selected, adherent, and monitored. Real-world patients have variable adherence, and oral semaglutide has strict dosing requirements (empty stomach, 120 mL water, 30-minute fast) that reduce compliance.

Persistence data show that roughly 60 to 70% of patients remain on oral semaglutide at 12 months, with GI side effects and cost being the primary reasons for discontinuation. Among patients who persist, glycemic durability mirrors the PIONEER trial-product estimates.

What PIONEER-1 Could Not Answer

Several questions remain open because PIONEER-1 (and the broader PIONEER program) was not designed to address them.

Cardiovascular outcomes. The SOUL trial (NCT03914326) is the dedicated cardiovascular outcomes trial for oral semaglutide. Results published in 2024 confirmed a statistically significant reduction in major adverse cardiovascular events (MACE), resolving a question that the PIONEER program could not. The PIONEER-1 dataset was too small and too short to detect cardiovascular differences.

Renal outcomes. Injectable semaglutide showed kidney-protective effects in the FLOW trial. Whether oral semaglutide confers the same renal benefit at 14 mg daily is not yet established by a dedicated renal outcomes trial.

Comparison to injectable semaglutide. PIONEER-9 and PIONEER-10 (conducted in Japan) compared oral and injectable semaglutide but used Japanese-specific doses. No head-to-head trial in a Western population at standard doses (oral 14 mg vs. injectable 1 mg) has been published.

Clinical Translation

For the prescriber deciding whether to start oral semaglutide based on PIONEER-1 data, the practical takeaways are:

The 1.5% A1C reduction at 26 weeks is real but represents peak pharmacologic effect. Expect 1.2 to 1.3% sustained reduction with continued use.
Stopping the drug leads to A1C rebound. This is a chronic therapy, not a course of treatment.
GI side effects are front-loaded and manageable with proper dose escalation.
The strict dosing protocol (fasting, water volume, post-dose fast) is a genuine adherence barrier that blunts real-world effectiveness compared to trial results.
Cardiovascular benefit is now supported by the SOUL trial, making oral semaglutide a reasonable choice in patients with established cardiovascular disease who prefer a tablet.

Frequently asked questions

›

References

Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724-1732. PubMed
Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272-2281. PubMed
U.S. Food and Drug Administration. Rybelsus (semaglutide) tablets prescribing information. September 2019. FDA Label
American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2023. Diabetes Care. 2023;46(Suppl 1). PubMed
Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-851. PubMed